Low Doses of Thalidomide (Thal) in Low Risk MDS with Transfusion-Dependant Anemia: The GFM THAL-SMD-200 Trial by Tamburini, J., Elie, C., Vassilief, D., Quarre, M.C., Beyne-Rauzy, O., Gardembas, M., Aouba, A., Berthou, C., Sanhes, L., Guerci, A., Stamatoullas, A., Bauduer, F., Sotto, J.J., Legros, L., Vaultier, S., Fenaux, P., Dreyfus, F., Bouscary, D.

Get full text

Thalidomide for the Treatment of Low Risk Myelodysplasia by Bouscary, D., Quarre, M.C., Vassilief, D., Rouzy, O. Beyne, Aouba, A., Berthou, C., Gardembas, C., Sanhes, L., Guerci, A., Mahe, B., Stamatoullas, A., Bauduer, F., Sotto, J.J., Legros, L., Vaultier, S., Fenaux, P., Dreyfus, F.

Get full text

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience by Park, S., Kelaidi, C., Grabar, S., Beyne-Rauzy, O., Cheze, S., Bardet, V., Escoffre-Barbe, M., Ravoet, C., Ferrant, A., Vey, N., Dombret, H., Mahe, B., Mannone, L., Legros, L., Aljassem, L., Stamatoullas, A., Vassilief, D., Quarre, M.C., Ades, L., Andrieux, V., Giraudier, S., de Botton, S., Casadevall, N., Fenaux, P., Dreyfus, F.

Get full text

Prevention of HLA Immunization With Leukocyte-Poor Packed Red Cells and Platelet Concentrates Obtained by Filtration by Andreu, G., Dewailly, J., Leberre, C., Quarre, M.C., Bidet, M.L., Tardivel, R., Devers, L., Lam, Y., Soreau, E., Boccaccio, C., Piard, N., Bidet, J.M., Genetet, B., Fauchet, R.

Get full text

High Response Rate to Darbopoetin Alfa in “Low Risk” MDS : Results of a Phase II Study by Mannone, L., Gardin, C., Quarre, M.C., Bernard, J.F., Giraudier, S., Rosenthal, E., Vassilief, D., Hamza, F., Park, S., Kiladjian, J.J., Vaultier, S., Beyne-Rouzy, Mo, Cheze, S., Voilliat, L., Agape, P., Dreyfus, F., Fenaux, P.

Get full text

O-71 High response rate to darbopoetin alpha and sustained response in low risk MDS by Mannone, L., Quarre, M.C., Bernard, J.F., Beyne-Rauzy, M.O., Vassilieff, D., Park, S., Cheze, S., Agape, P., Vaultier, S., Dreyfus, F., Fenaux, P.

Get full text